PainChek Reports Strong Quarterly Sales Growth – 3 July 2025
PCK – Application for quotation of securities – 6 June 2025
PCK – PainChek has productive final FDA De Novo clearance meeting – 5 June 2025
PCK – PainChek partners with Eldermark to expand US market reach – 27 May 2025
PCK – PainChek appoints head of Business Development for US market – 20 May 2025
PCK – Notification regarding unquoted securities – 19 May 2025
PCK – Notification of cessation of securities – 19 May 2025
PCK – Quarterly Investor Presentation April 2025
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 30 April 2025
PCK – Quarterly update and Appendix 4C webinar – 29 April 2025
PCK – R&D Tax Refund, FDA Review of Adult App & Infant App Launch – 16 April 2025
PCK – Appendix 2A – Application for quotation of securities – 27 March 2025
PCK – Update to previous announcement – 17 March 2025
PCK – PainChek NWR Investor Presentation Video – 17 March 2025
PCK – PainChek to present at NWR Virtual Healthcare – 17 March 2025
PCK – Notification regarding unquoted securities – 6 March 2025
PCK – Application for quotation of securities – 6 March 2025
PCK – Notification regarding unquoted securities – 5 March 2025
PCK – Half Yearly Report and Accounts – 28 February 2025
PCK – Results of Meeting – 26 February 2025
PCK – Quarterly Update and Appendix 4C – 31 January 2025
PCK – Quarterly update and Appendix 4C webinar – 30 January 2025
PCK – Notice of General Meeting/Proxy Form – 24 January 2025
PCK – Notification of cessation of securities – 24 December 2024
PCK – Appendix 3Y Change of Director’s Interest Notice – 23 December 2024
PCK – Application for quotation of securities – 19 December 2024
PCK – PainChek completes Entitlement Offer raising AUD $5.1 million – 16 December 2024
PCK – PainChek Entitlement Offer Open – 2 December 2024
PCK – Results of Meeting – 28 November 2024
PCK AGM watching the live feed – 27 November 2024
PCK – Proposed issue of securities – 25 November 2024
PCK – Prospectus – 25 November 2024
PCK – Underwritten Entitlement Offer to raise AUD $5.1million – 25 November 2024
PCK – Trading Halt – 21 November 2024
PCK submits application for Adult App FDA De Novo clearance – 20 November 2024
PCK – Addendum to BESTMED reseller agreement announcement – 19 November 2024
PCK – PainChek expands Australian market reach with BESTMED reseller agreement – 13 November 2024
PCK – Quarterly Investor Presentation – 30 October 2024
PCK – 30 September 2024 Quarterly Update and Appendix 4C – 3 October 2024
PCK – Appendix 4C quarterly webinar – 11am AEDT Wednesday 30 October 2024
PCK – Notice of Annual General Meeting/Proxy Form – 25 October 2024
PCK – Change of Director’s Interest Notice – 4 October 2024
PCK – Notification of cessation of securities – 4 October 2024
PCK – Application for quotation of securities – 2 October 2024
PCK – PainChek Adult app FDA De Novo submission update – 2 October 2024
PCK – Corporate Governance Statement & Appendix 4G 2024
PCK – Annual Report to shareholders – 30 September 2024
PCK – Notification of cessation of securities – 27 September 2024
PCK – Appendix 4E ASX Preliminary Final Report – 30 August 2024
PCK – Notification of cessation of securities – 2 August 2024
PCK – Investor Webinar Presentation – 30 July 2024
PCK – June 2024 Quarterly Update and Appendix 4C – 30 July 2024
PCK – Quarterly Update Webinar – 26 July 2024
PCK – PainChek receives European patent for pain assessment technology – 28 May 2024
PCK – Quarterly Activities/Appendix 4C Cash Flow Report – 31 March 2024
PCK – PainChek receives $1,210,000 R&D Tax Incentive Refund – 23 April 2024
PCK – Notice under Section 708A(5)(e) of the Corporation Act 2001 (Cth) – 20 March 2024
PCK – Appendix 2A – Application for quotation of securities – 20 March 2024
PainChek to present at NWR Virtual Healthcare Conference – 18 March 2024
PCK – Appendix 3Y Change of Director’s Interest Notice – 15 March 2024
PCK – Appendix 3B – Proposed issue of securities
PCK – PainChek completes A$5.0m capital raise with A$2.5m placement – 14 March 2024
PCK – Appendix 2A – Application of quotation securities – 11 March 2024
PCK – Completion of Security Purchase Plan – 11 March 2024
PCK – PainChek Share Purchase Plan oversubscribed – 7 March 2024
PCK – 4D and Half Year Report 31 Dec 2023 – 29 February 2024
PCK – Underwritten Share Purchase Plan to raise AUD $2.5 million – 14 February 2024
PCK – Appendix 3B – Proposed issue of securities – 14 February 2024
PCK – Request for Trading Halt – 12 February 2024
PCK – Quarterly Update and Appendix 4C – 31 December 2023
PCK – Cleansing Notice – 4 December 2023
PCK – Application for quotation & securities – 30 November 2023
PCK – Appendix 3Y Change of Director’s Interest Notice – 30 November 2023
PCK – 2023 Annual General Meeting – CEO Presentation – 22 November
PCK – Results of 2023 Annual General Meeting – 22 November 2023
PCK – Notice of Acceptance for European Patent – 21 November 2023
PCK – Notification regarding unquoted securities – 10 November 2023
PCK – PCK – Application for quotation of securities – 8 November 2023
PCK – Cleansing Notice – 8 November 2023
PCK – Application for quotation of securities – 3 November 2023
PCK – Change of Director’s Interest Notices x5 – 4 October 2023
Investor webinar presentation – Wednesday, 31 October 2023
Quarterly investor webinar – 11:30am AEDT Tuesday 31 October 2023
PCK Quarterly Update and Appendix 4C – 30 September 2023
PCK – Notification regarding unquoted securities – 15 October 2023
PCK – Appendix 3Y Change of Director’s Interest Notice – 30 September 2023
PCK – Financial Report for the year ended – 30 June 2023
PCK – 2023 Corporate Governance Statement – 30 June 2023
PCK – Cleansing Notice – 27 September 2023
PCK – Application for quotation of +securities – 27 September 2023
PCK – Cleansing Notice – 20 September 2023
PCK – Application for quotation of +securities – 20 September 2023
PCK – Proposed issue of securities – 19 September 2023
PCK – PainChek A$3.55m Placement – 14 September 2023
PCK Proposed issue of securities – 14 September 2023
PCK Investor Presentation – 14 September 2023
Appendix 4E ASX Preliminary Final Report – Year ended 30 June 2023
PCK FDA clinical study update August 2023
PainChek (ASX: PCK) Investor Webinar | July 2023
Investor Presentation Webinar and Quartlery Update – 27 July 2023
Quarterly Update and Appendix 4C – 30 June 2023
Quarterly Update and Appendix 4C report – 31 March 2023
Half Year Report and Appendix 4D half -year ended 31 December 2022
PainChek (ASX:PCK) Quarterly Update Webinar – January 2023
Investor Webinar Presentation – 31 January 2023
Quarterly Update and Appendix 4C cashflow report – 31 December 2022
PCK – 2022 AGM Results – 23 November 2022
PainChek® AGM Company Presentation – November 2022
Quarterly Update and Appendix 4C – 31 October 2022
Notice of Annual General Meeting – 18 October 2022
Director Nominations AGM – 14 October 2022
Response to ASX Query – 30 September 2022
PainChek® expands activities to Japan with JETRO Business Connect – 26 September 2022
Financial Statements 30 June 2022 & Appendix 4E – 31 August 2022
Investor Presentation – August 2022
PCK – Notification of cessation of securities – 9 August 2022
PCK – Application for quotation of securities – 2 August 2022
PCK – Results of Non-Renounceable Entitlement Offer – 29 July 2022
PainChek® receives funding for 12-month pilot in Welsh care homes – 26 July 2022
Investor Webinar Presentation – 7 July 2022
PainChek to Receive Government Funding for Children’s Disability App Development – 5 July 2022
PCK – Despatch of Documents for Entitlement Offer – 4th July 2022
PCK – Offer Booklet – 4 July 2022
PCK – Cleansing Notice Placement – 1 July 2022
PCK – Application for quotation of securities – 30 June 2022
PCK – Entitlement Offer Cleansing Notice – 24 June 2022
PCK – Proposed issue of securities – 24 June 2022
PCK – Investor Presentation – June 2022
PainChek $3.0m placement and underwritten $1.59m entitlement offer – 24 June 2022
PCK – Request for Trading Halt – 22 June 2022
PCK – Application for quotation of securities – 17 June 2022
CEO Q&A Video – Company Update – May 2022
2022 Investor Presentation Webinar – Tuesday 3rd May 2022
2022 Investor Presentation – 3 May 2022
2022 Quarterly Update and Appendix 4C – 31 March 2022
Appointment of Non-Executive Director – 30 March 2022
Appendix 3X – Initial Director’s Interest Notice – 30 March 2022
Summerset Holdings Limited rolls-out PainChek to all care centres in New Zealand – 28 March 2022
Half Year Report Appendix 4D – 28 February 2022
Supplementary Appendix 4C Announcement – 9 February 2022
Quarterly Update Investor Webinar – 31 January 2022
Quarterly Update Investor Presentation – 28 January 2022
December Quarterly Update and Appendix 4C – 31 December 2021
Clarification to Appendix 4C – 3 December 2021
Results of AGM – 30 November 2021
Response to ASX Price and Volume Query – 30 November 2021
AGM Investor Update – 30 November 2021
PainChek to present at NWR Virtual Healthcare Day – 22 November 2021
Notice of Annual General Meeting / Proxy Form – 27 October 2021
September Quarterly Update – 22 October 2021
Appendix 4C- Quarterly cash flow report entities subject to Listing Rule 4.7B – 22 October 2021
Appendix 3Y – Change of Director’s Interest Notice – 16 September 2021
PainChek Infant study published in Lancet Digital Health – 2 September 2021
Financial Report for the year ended 30 June 2021 – 31 August 2021
Appendix 4E Preliminary Final Report – 31 August 2021
PainChek NSW OSR Taxation Assessment – 27 August 2021
Cleansing Statement – 20 August 2021
Application for quotation of securities – 20 August 2021
June 2021 Quarterly Update – 29 July2021
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B – 30 June 2021
PainChek to present at NWR Virtual Investor conference – 29 July 2021
PainChek to receive $1.25M milestone payment from Department of Health- 28 June 2021
Change of Company Secretary – 2nd June 2021
PainChek Infant achieves regulatory clearance in multiple International markets – 20 May 2021
Appendix 3G Notification of issue, conversion or payment up of equity & securities – 18 May 2021
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B – 29 April 2021
PainChek receives CE Mark and TGA clearance for Universal app – 17 March 2021
PainChek to present at NWR Communications Virtual Investor Conference – 16 March 2021
Appendix 3G Notification of issue, conversion or payment up of equity & securities – 16 March 2021
Appendix 4D- Half Year Report to the Australian Securities Exchange – 25 February 2021
December 2020 Quarterly Update – 22 January 2021
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B – 22 January 2021
PainChek receives regulatory clearance from Health Canada – 19 November 2020
PainChek® to enter Canadian homecare market in partnership with AlayaCare – 28 October 2020
Confirmation of Release – PCK – PainChek Granted Patent in China – 14 August 2020
PainChek completes $10 million Placement – 11 August 2020
June 2020 Quarterly Update – 28 July 2020
Appendix 4E Preliminary Final Report to the Australian Securities Exchange – 30 June 2020
PainChek® AGM Company Presentation – November 2022
PainChek® plans Canadian regulatory clearance and market entry – 10 June 2020
PCK – Results of Meeting – 28 November 2021
PainChek® granted Australian patent for pain assessment invention – 8th May 2020
Appendix 4C – Quarterly cash flow report for entities subject to Listing Rule 4.7B – 31 March 2020
PainChek® submits FDA Pre-Submission Supplement- 14 April 2020
